ClinicalTrials.gg
CompletedNCT05452239RESOLUTIONUpdated Jan 29, 2026Results posted

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

A Phase 4 interventional study of Eptinezumab and Placebo in Migraine and Medication Overuse Headache, sponsored by H. Lundbeck A/S. Completed at 76 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
608
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
6th of 21
608 · median 193
Started
2022
with 1 other
Phase 4
4 of 21
1 open now
Registered
16th of 21
by date
Lead sponsor
12 of 21
H. Lundbeck A/S

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 6th largest by enrollment, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 16th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications.

Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with headache, and acute medication use in adults who have migraine and MOH.

Read the detailed description

The total study duration from screening visit to safety follow-up visit is approximately 36 weeks and includes a screening period (4 weeks), a placebo-controlled period (12 weeks), an open-label period (12 weeks), and a safety follow-up period (8 weeks).

03

Conditions studied

  • Migraine
  • Medication Overuse Headache

Keywords

  • Eptinezumab
  • Migraine
  • Medication overuse headache
  • Brief educational intervention
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a diagnosis of migraine or MOH as defined by IHS ICHD-3 guidelines confirmed at the Screening Visit.
  • The participant has ≥8 migraine days per month for each month within the past 3 months prior to the Screening Visit.
  • The participant has ≥15 headache days per month for each month within the past 3 months prior to the Screening Visit.
  • The participant has had an onset of migraine diagnosis at ≤50 years of age.

Exclusion criteria

Exclusion Criteria:

  • The participant has confounding and pain syndromes (for example, fibromyalgia, chronic low back pain, and complex regional pain syndrome).
  • The participant has a diagnosis of acute or active temporomandibular disorders.
  • The participant has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), recurrent painful ophthalmoplegic neuropathy, migraine with brainstem aura, and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration).
  • The participant has psychosis, bipolar mania, dementia, or any other psychiatric conditions whose symptoms are not controlled or who has not been adequately treated for a minimum of 6 months prior to the Screening Visit.
  • The participant has a history of clinically significant cardiovascular disease including uncontrolled hypertension, vascular ischaemia, or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
608 participants (actual)

Study arms

  • Experimental
    Eptinezumab

    Participants will receive an intravenous (IV) infusion of eptinezumab at Week 0 and Week 12.

    Drug: Eptinezumab

  • Placebo comparator
    Placebo

    Participants will receive a single IV infusion of matching placebo to eptinezumab at Week 0. Then, all participants will receive a single IV infusion of eptinezumab at Week 12.

    Drug: Eptinezumab · Drug: Placebo

Interventions

  • Solution for infusion

  • DrugPlacebo

    Solution for infusion

06

What researchers measure

Primary outcomes

  1. Placebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4

    A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

    Time frame: Baseline, Weeks 1 - 4

Secondary outcomes

  1. Placebo-controlled Period: Change From Baseline in MMDs at Weeks 1 to 12

    A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

    Time frame: Baseline, Weeks 1 - 12

  2. Placebo-controlled Period: Change From Baseline in the Number of Monthly Headache Days (MHDs) at Weeks 1 to 4 and Weeks 1 to 12

    A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).

    Time frame: Baseline, Weeks 1 - 4 and Weeks 1 - 12

  3. Placebo-controlled Period: Percentage of Participants Not Fulfilling the International Classification of Headache Disorders, 3rd Edition (ICHD-3) Diagnostic Criteria for Chronic Migraine (CM) Nor Medication Overuse Headache (MOH)

    CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis. MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.

    Time frame: Weeks 1 - 4 and Weeks 1 - 12

  4. Placebo-controlled Period: Change From Baseline in Average Daily Pain Assessment Score at Weeks 1 to 2

    Daily Pain assessment data were collected in the headache electronic diary (eDiary) via the question "What was the worst pain intensity of this headache today?". The pain intensity assessment was collected on a 3-point scale: Mild (score = 1), Moderate (score = 2), and Severe (score = 3). For each day, the Daily Pain assessment score was derived by averaging the worst pain intensity over all headaches of that day. For days on which no headaches took place during the relevant period, the Daily Pain score was given as a score of 0. The average Daily Pain score was calculated using the Daily Pain assessments collected during Weeks 1-2.

    Time frame: Baseline, Weeks 1 - 2

  5. Placebo-controlled Period: Change From Baseline in Monthly Days With Acute Migraine Medication Use at Weeks 1 to 4 and Weeks 1 to 12

    Acute migraine medication included those medications classified as opioid, barbiturates, ergotamine, triptan, non-opioid analgesic, and combination of analgesic ingredients.

    Time frame: Baseline, Weeks 1 - 4 and Weeks 1 - 12

  6. Open-label Period: Change From Baseline in MMDs at Weeks 13-16, 17-20, and 21-24

    A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

    Time frame: Baseline, Weeks 13-16, 17-20, and 21-24

  7. Open-label Period: Change From Baseline in the Number of MHDs at Weeks 13-16, 17-20, and 21-24

    A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).

    Time frame: Baseline, at Weeks 13-16, 17-20, and 21-24

  8. Open-label Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for CM Nor MOH at Weeks 13 to 24

    CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis. MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.

    Time frame: Weeks 13 - 24

  9. Open-label Period: Change From Baseline in Average Daily Pain Assessment Score at Weeks 13-16, 17-20, and 21-24

    Daily Pain assessment data were collected in the headache eDiary via the question "What was the worst pain intensity of this headache today?". The pain intensity assessment was collected on a 3-point scale: Mild (score = 1), Moderate (score = 2), and Severe (score = 3). For each day, the Daily Pain assessment score was derived by averaging the worst pain intensity over all headaches of that day. For days on which no headaches took place during the relevant period, the Daily Pain score was given as a score of 0. The average Daily Pain score was calculated using the Daily Pain assessments collected during Weeks 13-16, 17-20, and 21-24.

    Time frame: Baseline, Weeks 13-16, 17-20, and 21-24

  10. Open-label Period: Change From Baseline in Monthly Days With Acute Migraine Medication Use at Weeks 13-16, 17-20, and 21-24

    Acute migraine medication included paracetamol, triptans, ergotamine, combination of non-opioid analgesics, individual non-opioid analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs). Barbiturates and/or opioid analgesics were allowed when considered medically indicated providing its use does not exceed 4 days per month.

    Time frame: Baseline, Weeks 13-16, 17-20, and 21-24

  11. Placebo-controlled Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for CM at Weeks 1 to 4 and Weeks 1 to 12

    CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis.

    Time frame: Weeks 1 - 4 and Weeks 1 - 12

  12. Placebo-controlled Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for MOH at Weeks 1 to 4 and Weeks 1 to 12

    MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.

    Time frame: Weeks 1 - 4 and Weeks 1 - 12

  13. Placebo-controlled Period: Change From Baseline in MMDs With Use of Acute Headache Medication at Weeks 1 to 12

    A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

    Time frame: Baseline, Weeks 1 - 12

  14. Placebo-controlled Period: Change From Baseline in Monthly Days With Triptan or Ergotamine Medication Use at Weeks 1 to 12

    Time frame: Baseline, Weeks 1 - 12

  15. Open-label Period: Change From Baseline in Monthly Days With Triptan or Ergotamine Medication Use at Weeks 13-16, 17-20, and 21-24

    Time frame: Baseline, Weeks 13-16, 17-20, and 21-24

  16. Placebo-controlled Period: Change From Baseline in Monthly Days With Individual Non-opioid Analgesics or Non-steroidal Anti-inflammatory Drug (NSAID) Medication Use at Weeks 1 to 12

    Time frame: Baseline, Weeks 1 - 12

  17. Open-label Period: Change From Baseline in Monthly Days With Individual Non-opioid Analgesics or NSAID Medication Use at Weeks 13-16, 17-20, and 21-24

    Time frame: Baseline, Weeks 13-16, 17-20, and 21-24

  18. Placebo-controlled Period: Change From Baseline in Monthly Days With Combination Non-opioid Analgesics Medication Use at Weeks 1 to 12

    Time frame: Baseline, Weeks 1 - 12

  19. Placebo-controlled Period: Number of Participants With Migraine on the Day After Dosing

    Time frame: Day 1

  20. Placebo-controlled Period: Percentage of Participants With ≥50% Reduction From Baseline in MMDs at Weeks 1 to 4 and Weeks 1 to 12

    A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

    Time frame: Baseline to Weeks 1 - 4 and 1 - 12

  21. Placebo-controlled Period: Percentage of Participants With ≥75% Reduction From Baseline in MMDs at Weeks 1 to 4 and Weeks 1 to 12

    A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

    Time frame: Baseline to Weeks 1 - 4 and 1 - 12

  22. Placebo-controlled Period: Percentage of Participants With ≥50% Reduction From Baseline in MHDs at Weeks 1 to 4 and Weeks 1 to 12

    A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).

    Time frame: Baseline to Weeks 1 - 4 and 1 - 12

  23. Placebo-controlled Period: Percentage of Participants With ≥75% Reduction From Baseline in MHDs at Weeks 1 to 4 and Weeks 1 to 12

    A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).

    Time frame: Baseline to Weeks 1 - 4 and 1 - 12

  24. Placebo-controlled Period: Change From Baseline in Percentage of Migraine Attacks With Severe Pain Intensity at Weeks 1 to 4 and Weeks 1 to 12

    A migraine that fulfilled the criteria for a migraine, was referred to as a migraine attack.

    Time frame: Baseline to Weeks 1 - 4 and 1 - 12

  25. Placebo-controlled Period: Change From Baseline in Percentages of Headache Episodes With Severe Pain Intensity at Weeks 1 to 4 and Weeks 1 to 12

    A non-migraine headache that lasted ≥30 minutes or a migraine headache, was referred to as a headache episode.

    Time frame: Baseline to Weeks 1 - 4 and 1 - 12

  26. Placebo-controlled Period: Patient Global Impression of Change (PGIC) Score at Weeks 4 and 12

    The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.

    Time frame: Weeks 4 and 12

  27. Open-label Period: PGIC Score at Week 24

    The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.

    Time frame: Week 24

  28. Placebo-controlled Period: Most Bothersome Symptom (MBS) Score at Week 12

    Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.

    Time frame: Week 12

  29. Open-label Period: MBS Score at Week 24

    Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.

    Time frame: Week 24

  30. Placebo-controlled Period: Change From Baseline in Headache Impact Test (HIT-6) Total Score at Weeks 4 and 12

    The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

    Time frame: Baseline, Weeks 4 and 12

  31. Open-label Period: Change From Baseline in HIT-6 Total Score at Week 24

    The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

    Time frame: Week 24

  32. Placebo-controlled Period: Change From Baseline in Modified Migraine Disability Assessment (mMIDAS) Total Score at Weeks 4 and 12

    The mMIDAS is a self-administered questionnaire that contains 7 questions about the headache a participant had in the previous month. The first 5 questions assess the impact of migraine on 3 domains of daily activity: 2 questions for paid work or schoolwork, 2 questions for household work, and 1 question for family, social and leisure activities. The 2 questions for each of the first two groups assess, respectively, the number of days off due to headache, and the number of days in which the productivity was reduced by half or more. mMIDAS total score was derived from the sum of the answers on the first 5 questions. Total score ranged from 0 (little/no disability) to 20 (severe disability) with higher scores indicating more severe disability.

    Time frame: Baseline, Weeks 4 and 12

  33. Open-label Period: Change From Baseline in mMIDAS Total Score at Week 24

    The mMIDAS is a self-administered questionnaire that contains 7 questions about the headache a participant had in the previous month. The first 5 questions assess the impact of migraine on 3 domains of daily activity: 2 questions for paid work or schoolwork, 2 questions for household work, and 1 question for family, social and leisure activities. The 2 questions for each of the first two groups assess, respectively, the number of days off due to headache, and the number of days in which the productivity was reduced by half or more. mMIDAS total score was derived from the sum of the answers on the first 5 questions. Total score ranged from 0 (little/no disability) to 20 (severe disability) with higher scores indicating more severe disability.

    Time frame: Baseline, Week 24

  34. Placebo-controlled Period: Change From Baseline in Migraine-Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Weeks 4 and 12

    The MSQ v2.1 is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0-to-100-point scale. Higher scores indicated better quality of life.

    Time frame: Baseline, Weeks 4 and 12

  35. Open-label Period: Change From Baseline in MSQ v2.1 Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 24

    The MSQ v2.1 is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0-to-100-point scale. Higher scores indicated better quality of life.

    Time frame: Baseline, Weeks 24

  36. Placebo-controlled Period: Change From Baseline in Euroqol 5 Dimension - 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Weeks 4 and 12

    The EQ-5D-5L VAS measures participant's self-rated health-related quality of life on a VAS. The VAS score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline, Weeks 4 and 12

  37. Open-label Period: Change From Baseline in EQ-5D-5L VAS Score at Week 24

    The EQ-5D-5L VAS measures participant's self-rated health-related quality of life on a VAS. The VAS score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Week 24

  38. Placebo-controlled Period: Change From Baseline in Work Productivity and Activity Impairment: Migraine (WPAI:M) Sub-scores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 12

    The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

    Time frame: Baseline, Week 12

  39. Open-label Period: Change From Baseline in WPAI:M Sub-scores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 24

    The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

    Time frame: Baseline, Week 24

  40. Placebo-controlled Period: Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Subscale (Depression and Anxiety) Scores at Weeks 4 and 12

    The HADS is a participant-rated scale designed to assess psychological distress in non-psychiatric participants. The HADS consists of 2 sub-scales: depression and anxiety. Each sub-scale contains 7 items, and each item was rated from 0 (absent) to 3 (maximum severity). The total score of each sub-scale ranged from 0 (absent) to 21 (maximum severity). Higher scores indicated higher severity.

    Time frame: Baseline, Weeks 4 and 12

  41. Open-label Period: Change From Baseline in HADS Subscale (Depression and Anxiety) Scores at Week 24

    The HADS is a participant-rated scale designed to assess psychological distress in non-psychiatric participants. The HADS consists of 2 sub-scales: depression and anxiety. Each sub-scale contains 7 items, and each item was rated from 0 (absent) to 3 (maximum severity). The total score of each sub-scale ranged from 0 (absent) to 21 (maximum severity). Higher scores indicated higher severity.

    Time frame: Baseline, Week 24

  42. Placebo-controlled Period: Treatment Satisfaction Questionnaire for Medicine - 9 Items (TSQM-9) Score at Weeks 4 and 12

    TSQM is a 14-item instrument consisting of four scales: effectiveness scale (questions 1 to 3), side effects scale (questions 4 to 8), convenience scale (questions 9 to 11) and global satisfaction scale (questions 12 to 14). In TSQM-9, the five items related to side effects of medication were not included. The scores were computed by adding items for each domain. The lowest possible score was subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.

    Time frame: Weeks 4 and 12

  43. Open-label Period: TSQM-9 Score at Week 24

    TSQM is a 14-item instrument consisting of four scales: effectiveness scale (questions 1 to 3), side effects scale (questions 4 to 8), convenience scale (questions 9 to 11) and global satisfaction scale (questions 12 to 14). In TSQM-9, the five items related to side effects of medication were not included. The scores were computed by adding items for each domain. The lowest possible score was subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.

    Time frame: Baseline, Week 24

  44. Placebo-controlled Period: Migraine Specific Health Care Resource Utilization (HCRU) - Visits to a Family Doctor/General Practitioner at Baseline and Week 12

    Number of participants who visited to a family doctor/general practitioner during the past 4 weeks has been reported at Baseline and Week 12.

    Time frame: Baseline and Week 12

  45. Placebo-controlled Period: Migraine Specific HCRU - Visits to a Specialist at Baseline and Week 12

    Number of participants who visited a specialist during the past 4 weeks has been reported at Baseline and Week 12.

    Time frame: Baseline and Week 12

  46. Placebo-controlled Period: Migraine Specific HCRU - Number of Emergency Department Visits Due to Migraine at Baseline and Week 12

    Number of participants who visited to the emergency department due to migraine during the past 4 weeks has been reported at Baseline and Week 12.

    Time frame: Baseline and Week 12

  47. Placebo-controlled Period: Migraine Specific HCRU - Number of Hospital Admissions Migraine at Baseline and Week 12

    Number of participants who were admitted to the hospital during the past 4 weeks due to migraine has been reported at Baseline and Week 12.

    Time frame: Baseline and Week 12

  48. Placebo-controlled Period: Migraine Specific HCRU - Total Number of Participants With Overnight Hospital Stays Due to Migraine at Baseline and Week 12

    Number of participants who had overnight hospital stays during the past 4 weeks due to migraine has been reported at Baseline and Week 12.

    Time frame: Baseline and Week 12

  49. Open-label Period: Migraine Specific HCRU - Visits to a Family Doctor/General Practitioner at Week 24

    Number of participants who visited a family doctor/general practitioner has been reported.

    Time frame: Week 24

  50. Open-label Period: Migraine Specific HCRU - Visits to a Specialist at Week 24

    Number of participants who visited a specialist has been reported.

    Time frame: Week 24

  51. Open-label Period: Migraine Specific HCRU - Number of Participants With Emergency Department Visits Due to Migraine at Week 24

    Number of participants who visited the emergency department due to migraine has been reported.

    Time frame: Week 24

  52. Open-label Period: Migraine Specific HCRU - Number of Participants With Hospital Admissions Due to Migraine at Week 24

    Number of participants who admitted in the hospital due to migraine has been reported.

    Time frame: Week 24

  53. Open-label Period: Migraine Specific HCRU - Number of Participants With Overnight Hospital Stays Due to Migraine at Week 24

    Number of participants with overnight hospital stays due to migraine has been reported.

    Time frame: Week 24

07

Results

Posted Dec 4, 2025

Participant flow

Placebo-controlled Period
Participant flow — Placebo-controlled Period
MilestoneEptinezumabPlacebo
Started305303
Received at least 1 dose of study drug303301
Full analysis set (fas)302300
Completed301295
Not completed48
Withdrew: Withdrawal by subject04
Withdrew: Lost to follow-up10
Withdrew: Failure to comply with trial procedures01
Withdrew: Randomized but not treated22
Withdrew: Other than specified11
Open-label Period
Participant flow — Open-label Period
MilestoneEptinezumabPlacebo
Started300293
Received at least 1 dose of study drug300293
Completed294290
Not completed63
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up30
Withdrew: Other than specified12

Outcome measures

PrimaryPlacebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4

A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

Time frame:
Baseline, Weeks 1 - 4
Reported as:
Least squares mean · days/month
Placebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4
days/monthPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Placebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4-6.85 ± 0.518-3.66 ± 0.519
Statistical analysis
  • Placebo-controlled Period: Eptinezumab vs Placebo-controlled Period: Placebo · Mixed model for repeated measures · p = <0.0001 (Testing continued only if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 1 of testing order.) · Least square (ls) mean difference: -3.20 · 95% CI -4.16 to -2.23
SecondaryPlacebo-controlled Period: Change From Baseline in MMDs at Weeks 1 to 12

A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

Time frame:
Baseline, Weeks 1 - 12
Reported as:
Least squares mean · days/month
Placebo-controlled Period: Change From Baseline in MMDs at Weeks 1 to 12
days/monthPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Placebo-controlled Period: Change From Baseline in MMDs at Weeks 1 to 12-7.44 ± 0.508-4.50 ± 0.508
Statistical analysis
  • Placebo-controlled Period: Eptinezumab vs Placebo-controlled Period: Placebo · Mixed model for repeated measures · p = <0.0001 (Testing continued only if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 2 of testing order.) · Ls mean difference: -2.94 · 95% CI -3.86 to -2.02
SecondaryPlacebo-controlled Period: Change From Baseline in the Number of Monthly Headache Days (MHDs) at Weeks 1 to 4 and Weeks 1 to 12

A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).

Time frame:
Baseline, Weeks 1 - 4 and Weeks 1 - 12
Reported as:
Least squares mean · days/month
Placebo-controlled Period: Change From Baseline in the Number of Monthly Headache Days (MHDs) at Weeks 1 to 4 and Weeks 1 to 12
days/monthPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Change at Weeks 1-4-6.54 ± 0.502-3.40 ± 0.502
Change at Weeks 1-12-7.38 ± 0.497-4.45 ± 0.497
Statistical analysis
  • Placebo-controlled Period: Eptinezumab vs Placebo-controlled Period: Placebo · Mixed model for repeated measures · p = <0.0001 (Testing continued only if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 3 of testing order.) · Ls mean difference: -3.15 · 95% CI -4.07 to -2.22Change From Baseline in the Number of MHDs at Weeks 1 to 4: Eptinezumab vs. Placebo
  • Placebo-controlled Period: Eptinezumab vs Placebo-controlled Period: Placebo · Mixed model for repeated measures · p = <0.0001 (Testing continued only if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 4 of testing order.) · Ls mean difference: -2.93 · 95% CI -3.83 to -2.02Change From Baseline in the Number of MHDs at Weeks 1 to 12 (averaged over three 4-week intervals): Eptinezumab vs. Placebo
SecondaryPlacebo-controlled Period: Percentage of Participants Not Fulfilling the International Classification of Headache Disorders, 3rd Edition (ICHD-3) Diagnostic Criteria for Chronic Migraine (CM) Nor Medication Overuse Headache (MOH)

CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis. MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.

Time frame:
Weeks 1 - 4 and Weeks 1 - 12
Reported as:
Number · percentage of participants
Placebo-controlled Period: Percentage of Participants Not Fulfilling the International Classification of Headache Disorders, 3rd Edition (ICHD-3) Diagnostic Criteria for Chronic Migraine (CM) Nor Medication Overuse Headache (MOH)
percentage of participantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Weeks 1-437.818.1
Weeks 1-1227.212.7
Statistical analysis
  • Placebo-controlled Period: Eptinezumab vs Placebo-controlled Period: Placebo · Regression, Logistic · p = <0.0001 (Testing continued only if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 5 of testing order.) · Odds ratio (or): 3.26 · 95% CI 2.18 to 4.94Percentage of participants not fulfilling the ICHD-3 Diagnostic Criteria for CM nor MOH at Weeks 1 to 4: Eptinezumab vs. Placebo
  • Placebo-controlled Period: Eptinezumab vs Placebo-controlled Period: Placebo · Regression, Logistic · p = <0.0001 (Testing continued only if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 6 of testing order.) · Odds ratio (or): 3.05 · 95% CI 1.93 to 4.90Percentage of participants not fulfilling the ICHD-3 Diagnostic Criteria for CM nor MOH at Weeks 1 - 12 (averaged over three 4-week intervals): Eptinezumab vs. Placebo
SecondaryPlacebo-controlled Period: Change From Baseline in Average Daily Pain Assessment Score at Weeks 1 to 2

Daily Pain assessment data were collected in the headache electronic diary (eDiary) via the question "What was the worst pain intensity of this headache today?". The pain intensity assessment was collected on a 3-point scale: Mild (score = 1), Moderate (score = 2), and Severe (score = 3). For each day, the Daily Pain assessment score was derived by averaging the worst pain intensity over all headaches of that day. For days on which no headaches took place during the relevant period, the Daily Pain score was given as a score of 0. The average Daily Pain score was calculated using the Daily Pain assessments collected during Weeks 1-2.

Time frame:
Baseline, Weeks 1 - 2
Reported as:
Least squares mean · units on a scale
Placebo-controlled Period: Change From Baseline in Average Daily Pain Assessment Score at Weeks 1 to 2
units on a scalePlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Placebo-controlled Period: Change From Baseline in Average Daily Pain Assessment Score at Weeks 1 to 2-0.58 ± 0.048-0.27 ± 0.048
Statistical analysis
  • Placebo-controlled Period: Eptinezumab vs Placebo-controlled Period: Placebo · ANCOVA · p = <0.0001 (Testing continued only if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 7 of testing order.) · Ls mean difference: -0.31 · 95% CI -0.39 to -0.22
SecondaryPlacebo-controlled Period: Change From Baseline in Monthly Days With Acute Migraine Medication Use at Weeks 1 to 4 and Weeks 1 to 12

Acute migraine medication included those medications classified as opioid, barbiturates, ergotamine, triptan, non-opioid analgesic, and combination of analgesic ingredients.

Time frame:
Baseline, Weeks 1 - 4 and Weeks 1 - 12
Reported as:
Least squares mean · days/month
Placebo-controlled Period: Change From Baseline in Monthly Days With Acute Migraine Medication Use at Weeks 1 to 4 and Weeks 1 to 12
days/monthPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Change at Weeks 1-4-11.32 ± 0.508-7.69 ± 0.509
Change at Weeks 1-12-11.18 ± 0.490-7.83 ± 0.490
Statistical analysis
  • Placebo-controlled Period: Eptinezumab vs Placebo-controlled Period: Placebo · Mixed model for repeated measures · p = <0.0001 (Testing continued only if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 8 of testing order.) · Ls mean difference: -3.63 · 95% CI -4.59 to -2.67Change from baseline in monthly days with acute migraine medication use at Weeks 1 to 4: Eptinezumab vs. Placebo
  • Placebo-controlled Period: Eptinezumab vs Placebo-controlled Period: Placebo · Mixed model for repeated measures · p = <0.0001 (Testing continued only if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 9 of testing order.) · Ls mean difference: -3.35 · 95% CI -4.23 to -2.48Change from baseline in monthly days with acute migraine medication use at Weeks 1 - 12 (averaged over three 4-week intervals): Eptinezumab vs. Placebo
SecondaryOpen-label Period: Change From Baseline in MMDs at Weeks 13-16, 17-20, and 21-24

A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

Time frame:
Baseline, Weeks 13-16, 17-20, and 21-24
Reported as:
Mean · days/month
Open-label Period: Change From Baseline in MMDs at Weeks 13-16, 17-20, and 21-24
days/monthOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Change at Weeks 13-16-10.23 ± 7.167-10.08 ± 7.136
Change at Weeks 17-20-10.29 ± 7.093-10.29 ± 7.301
Change at Weeks 21-24-9.24 ± 7.220-9.30 ± 7.602
SecondaryOpen-label Period: Change From Baseline in the Number of MHDs at Weeks 13-16, 17-20, and 21-24

A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).

Time frame:
Baseline, at Weeks 13-16, 17-20, and 21-24
Reported as:
Mean · days/month
Open-label Period: Change From Baseline in the Number of MHDs at Weeks 13-16, 17-20, and 21-24
days/monthOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Change at Weeks 13-16-10.31 ± 7.113-9.99 ± 7.082
Change at Weeks 17-20-10.46 ± 6.941-10.34 ± 7.253
Change at Weeks 21-24-9.46 ± 7.206-9.47 ± 7.382
SecondaryOpen-label Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for CM Nor MOH at Weeks 13 to 24

CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis. MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.

Time frame:
Weeks 13 - 24
Reported as:
Number · percentage of participants
Open-label Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for CM Nor MOH at Weeks 13 to 24
percentage of participantsOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Open-label Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for CM Nor MOH at Weeks 13 to 2438.940.2
SecondaryOpen-label Period: Change From Baseline in Average Daily Pain Assessment Score at Weeks 13-16, 17-20, and 21-24

Daily Pain assessment data were collected in the headache eDiary via the question "What was the worst pain intensity of this headache today?". The pain intensity assessment was collected on a 3-point scale: Mild (score = 1), Moderate (score = 2), and Severe (score = 3). For each day, the Daily Pain assessment score was derived by averaging the worst pain intensity over all headaches of that day. For days on which no headaches took place during the relevant period, the Daily Pain score was given as a score of 0. The average Daily Pain score was calculated using the Daily Pain assessments collected during Weeks 13-16, 17-20, and 21-24.

Time frame:
Baseline, Weeks 13-16, 17-20, and 21-24
Reported as:
Mean · units on a scale
Open-label Period: Change From Baseline in Average Daily Pain Assessment Score at Weeks 13-16, 17-20, and 21-24
units on a scaleOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Change at Weeks 13-16-0.90 ± 0.628-0.90 ± 0.602
Change at Weeks 17-20-0.88 ± 0.641-0.89 ± 0.630
Change at Weeks 21-24-0.84 ± 0.638-0.81 ± 0.667
SecondaryOpen-label Period: Change From Baseline in Monthly Days With Acute Migraine Medication Use at Weeks 13-16, 17-20, and 21-24

Acute migraine medication included paracetamol, triptans, ergotamine, combination of non-opioid analgesics, individual non-opioid analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs). Barbiturates and/or opioid analgesics were allowed when considered medically indicated providing its use does not exceed 4 days per month.

Time frame:
Baseline, Weeks 13-16, 17-20, and 21-24
Reported as:
Mean · days/month
Open-label Period: Change From Baseline in Monthly Days With Acute Migraine Medication Use at Weeks 13-16, 17-20, and 21-24
days/monthOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Change at Weeks 13-16-12.08 ± 6.738-11.67 ± 6.470
Change at Weeks 17-20-11.82 ± 6.690-11.39 ± 7.080
Change at Weeks 21-24-10.96 ± 6.693-10.44 ± 7.338
SecondaryPlacebo-controlled Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for CM at Weeks 1 to 4 and Weeks 1 to 12

CM: - Headache on ≥15 days/month for \>3 months. - Participants had experienced ≥5 attacks that fulfilled the criteria for either migraine without aura or with aura. - On ≥8 days/month for \>3 months, headache meeting the criteria for either: Migraine without aura (headache with ≥2 of these features: unilateral location, pulsating quality, moderate to severe pain, or aggravation by physical activity; plus either nausea/vomiting or photophobia/phonophobia); Migraine with aura (headache preceded or accompanied by transient focal neurological symptoms, such as visual or sensory disturbances); or headache believed to be migraine by participant and relieved by a triptan or ergot derivative. - Not better accounted for by another ICHD-3 diagnosis.

Time frame:
Weeks 1 - 4 and Weeks 1 - 12
Reported as:
Number · percentage of participants
Placebo-controlled Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for CM at Weeks 1 to 4 and Weeks 1 to 12
percentage of participantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Weeks 1-455.032.4
Weeks 1-1244.423.0
SecondaryPlacebo-controlled Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for MOH at Weeks 1 to 4 and Weeks 1 to 12

MOH: Headache occurring on ≥15 days/month with a pre-existing headache. - Regular overuse for \>3 months of ≥1 drug that can be taken for acute and/or symptomatic treatment of headache. - Not better accounted for by another ICHD-3 diagnosis.

Time frame:
Weeks 1 - 4 and Weeks 1 - 12
Reported as:
Number · percentage of participants
Placebo-controlled Period: Percentage of Participants Not Fulfilling the ICHD-3 Diagnostic Criteria for MOH at Weeks 1 to 4 and Weeks 1 to 12
percentage of participantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Weeks 1-452.231.9
Weeks 1-1240.124.0
SecondaryPlacebo-controlled Period: Change From Baseline in MMDs With Use of Acute Headache Medication at Weeks 1 to 12

A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

Time frame:
Baseline, Weeks 1 - 12
Reported as:
Least squares mean · days/month
Placebo-controlled Period: Change From Baseline in MMDs With Use of Acute Headache Medication at Weeks 1 to 12
days/monthPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Placebo-controlled Period: Change From Baseline in MMDs With Use of Acute Headache Medication at Weeks 1 to 12-10.32 ± 0.481-7.16 ± 0.481
SecondaryPlacebo-controlled Period: Change From Baseline in Monthly Days With Triptan or Ergotamine Medication Use at Weeks 1 to 12
Time frame:
Baseline, Weeks 1 - 12
Reported as:
Least squares mean · days/month
Placebo-controlled Period: Change From Baseline in Monthly Days With Triptan or Ergotamine Medication Use at Weeks 1 to 12
days/monthPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Placebo-controlled Period: Change From Baseline in Monthly Days With Triptan or Ergotamine Medication Use at Weeks 1 to 12-8.35 ± 0.411-5.49 ± 0.409
SecondaryOpen-label Period: Change From Baseline in Monthly Days With Triptan or Ergotamine Medication Use at Weeks 13-16, 17-20, and 21-24
Time frame:
Baseline, Weeks 13-16, 17-20, and 21-24
Reported as:
Mean · days/month
Open-label Period: Change From Baseline in Monthly Days With Triptan or Ergotamine Medication Use at Weeks 13-16, 17-20, and 21-24
days/monthOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Change at Weeks 13-16-8.70 ± 6.736-8.79 ± 6.781
Change at Weeks 17-20-8.24 ± 6.540-8.31 ± 6.982
Change at Weeks 21-24-7.43 ± 6.505-7.56 ± 6.700
SecondaryPlacebo-controlled Period: Change From Baseline in Monthly Days With Individual Non-opioid Analgesics or Non-steroidal Anti-inflammatory Drug (NSAID) Medication Use at Weeks 1 to 12
Time frame:
Baseline, Weeks 1 - 12
Reported as:
Least squares mean · days/month
Placebo-controlled Period: Change From Baseline in Monthly Days With Individual Non-opioid Analgesics or Non-steroidal Anti-inflammatory Drug (NSAID) Medication Use at Weeks 1 to 12
days/monthPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Placebo-controlled Period: Change From Baseline in Monthly Days With Individual Non-opioid Analgesics or Non-steroidal Anti-inflammatory Drug (NSAID) Medication Use at Weeks 1 to 12-5.94 ± 0.402-4.80 ± 0.402
SecondaryOpen-label Period: Change From Baseline in Monthly Days With Individual Non-opioid Analgesics or NSAID Medication Use at Weeks 13-16, 17-20, and 21-24
Time frame:
Baseline, Weeks 13-16, 17-20, and 21-24
Reported as:
Mean · days/month
Open-label Period: Change From Baseline in Monthly Days With Individual Non-opioid Analgesics or NSAID Medication Use at Weeks 13-16, 17-20, and 21-24
days/monthOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Change at Weeks 13-16-6.55 ± 7.205-6.66 ± 7.108
Change at Weeks 17-20-6.65 ± 7.193-6.62 ± 7.316
Change at Weeks 21-24-6.18 ± 7.018-6.44 ± 7.468
SecondaryPlacebo-controlled Period: Change From Baseline in Monthly Days With Combination Non-opioid Analgesics Medication Use at Weeks 1 to 12
Time frame:
Baseline, Weeks 1 - 12
Reported as:
Least squares mean · days/month
Placebo-controlled Period: Change From Baseline in Monthly Days With Combination Non-opioid Analgesics Medication Use at Weeks 1 to 12
days/monthPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Placebo-controlled Period: Change From Baseline in Monthly Days With Combination Non-opioid Analgesics Medication Use at Weeks 1 to 12-1.24 ± 0.202-1.12 ± 0.201
SecondaryPlacebo-controlled Period: Number of Participants With Migraine on the Day After Dosing
Time frame:
Day 1
Reported as:
Count of participants · Participants
Placebo-controlled Period: Number of Participants With Migraine on the Day After Dosing
ParticipantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Placebo-controlled Period: Number of Participants With Migraine on the Day After Dosing162203
SecondaryPlacebo-controlled Period: Percentage of Participants With ≥50% Reduction From Baseline in MMDs at Weeks 1 to 4 and Weeks 1 to 12

A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

Time frame:
Baseline to Weeks 1 - 4 and 1 - 12
Reported as:
Number · percentage of participants
Placebo-controlled Period: Percentage of Participants With ≥50% Reduction From Baseline in MMDs at Weeks 1 to 4 and Weeks 1 to 12
percentage of participantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Weeks 1-436.713.7
Weeks 1-1240.418.0
SecondaryPlacebo-controlled Period: Percentage of Participants With ≥75% Reduction From Baseline in MMDs at Weeks 1 to 4 and Weeks 1 to 12

A Migraine Day was defined as a day with a headache if it belonged to any subgroup of headaches that: * lasted ≥30 minutes and met following 2 criteria: - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * lasted ≥30 minutes and participant had an aura with headache. * lasted ≥30 minutes and met 2 of following 3 criteria: - lasted 4 hours; - ≥2 of following characteristics: unilateral location; pulsating quality, moderate or severe pain intensity, or aggravation by or causing avoidance of routine physical activity; - During headache participant had ≥1 of following: nausea, vomiting, photophobia and phonophobia. * A day with a headache that was successfully treated with a migraine specific treatment. * A day with an aura without a headache with medication taken.

Time frame:
Baseline to Weeks 1 - 4 and 1 - 12
Reported as:
Number · percentage of participants
Placebo-controlled Period: Percentage of Participants With ≥75% Reduction From Baseline in MMDs at Weeks 1 to 4 and Weeks 1 to 12
percentage of participantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Weeks 1-413.04.3
Weeks 1-1212.95.3
SecondaryPlacebo-controlled Period: Percentage of Participants With ≥50% Reduction From Baseline in MHDs at Weeks 1 to 4 and Weeks 1 to 12

A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).

Time frame:
Baseline to Weeks 1 - 4 and 1 - 12
Reported as:
Number · percentage of participants
Placebo-controlled Period: Percentage of Participants With ≥50% Reduction From Baseline in MHDs at Weeks 1 to 4 and Weeks 1 to 12
percentage of participantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Weeks 1-433.011.0
Weeks 1-1235.815.3
SecondaryPlacebo-controlled Period: Percentage of Participants With ≥75% Reduction From Baseline in MHDs at Weeks 1 to 4 and Weeks 1 to 12

A headache day was defined as a day with a headache that lasted ≥30 minutes or that met the definition of a migraine day (as defined in outcome measure 1).

Time frame:
Baseline to Weeks 1 - 4 and 1 - 12
Reported as:
Number · percentage of participants
Placebo-controlled Period: Percentage of Participants With ≥75% Reduction From Baseline in MHDs at Weeks 1 to 4 and Weeks 1 to 12
percentage of participantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Weeks 1-49.33.3
Weeks 1-1210.95.3
SecondaryPlacebo-controlled Period: Change From Baseline in Percentage of Migraine Attacks With Severe Pain Intensity at Weeks 1 to 4 and Weeks 1 to 12

A migraine that fulfilled the criteria for a migraine, was referred to as a migraine attack.

Time frame:
Baseline to Weeks 1 - 4 and 1 - 12
Reported as:
Least squares mean · percentage of migraine attacks
Placebo-controlled Period: Change From Baseline in Percentage of Migraine Attacks With Severe Pain Intensity at Weeks 1 to 4 and Weeks 1 to 12
percentage of migraine attacksPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Change at Weeks 1-4-10.30 ± 1.912-1.60 ± 1.916
Change at Weeks 1-12-5.21 ± 1.859-1.60 ± 1.860
SecondaryPlacebo-controlled Period: Change From Baseline in Percentages of Headache Episodes With Severe Pain Intensity at Weeks 1 to 4 and Weeks 1 to 12

A non-migraine headache that lasted ≥30 minutes or a migraine headache, was referred to as a headache episode.

Time frame:
Baseline to Weeks 1 - 4 and 1 - 12
Reported as:
Least squares mean · percentage of headache episodes
Placebo-controlled Period: Change From Baseline in Percentages of Headache Episodes With Severe Pain Intensity at Weeks 1 to 4 and Weeks 1 to 12
percentage of headache episodesPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Change at Weeks 1-4-11.78 ± 1.867-3.36 ± 1.872
Change at Weeks 1-12-6.99 ± 1.822-2.79 ± 1.825
SecondaryPlacebo-controlled Period: Patient Global Impression of Change (PGIC) Score at Weeks 4 and 12

The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.

Time frame:
Weeks 4 and 12
Reported as:
Least squares mean · units on a scale
Placebo-controlled Period: Patient Global Impression of Change (PGIC) Score at Weeks 4 and 12
units on a scalePlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Week 42.62 ± 0.1003.63 ± 0.100
Week 122.64 ± 0.1013.54 ± 0.101
SecondaryOpen-label Period: PGIC Score at Week 24

The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.

Time frame:
Week 24
Reported as:
Mean · units on a scale
Open-label Period: PGIC Score at Week 24
units on a scaleOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Open-label Period: PGIC Score at Week 242.3 ± 1.182.3 ± 1.20
SecondaryPlacebo-controlled Period: Most Bothersome Symptom (MBS) Score at Week 12

Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.

Time frame:
Week 12
Reported as:
Least squares mean · units on a scale
Placebo-controlled Period: Most Bothersome Symptom (MBS) Score at Week 12
units on a scalePlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Placebo-controlled Period: Most Bothersome Symptom (MBS) Score at Week 122.87 ± 0.1063.59 ± 0.107
SecondaryOpen-label Period: MBS Score at Week 24

Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.

Time frame:
Week 24
Reported as:
Mean · units on a scale
Open-label Period: MBS Score at Week 24
units on a scaleOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Open-label Period: MBS Score at Week 242.6 ± 1.222.6 ± 1.25
SecondaryPlacebo-controlled Period: Change From Baseline in Headache Impact Test (HIT-6) Total Score at Weeks 4 and 12

The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Least squares mean · units on a scale
Placebo-controlled Period: Change From Baseline in Headache Impact Test (HIT-6) Total Score at Weeks 4 and 12
units on a scalePlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Change at Week 4-6.5 ± 7.25-2.6 ± 5.30
Change at Week 12-7.4 ± 8.60-3.9 ± 6.42
SecondaryOpen-label Period: Change From Baseline in HIT-6 Total Score at Week 24

The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

Time frame:
Week 24
Reported as:
Mean · units on a scale
Open-label Period: Change From Baseline in HIT-6 Total Score at Week 24
units on a scaleOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Open-label Period: Change From Baseline in HIT-6 Total Score at Week 24-8.1 ± 8.21-7.6 ± 7.74
SecondaryPlacebo-controlled Period: Change From Baseline in Modified Migraine Disability Assessment (mMIDAS) Total Score at Weeks 4 and 12

The mMIDAS is a self-administered questionnaire that contains 7 questions about the headache a participant had in the previous month. The first 5 questions assess the impact of migraine on 3 domains of daily activity: 2 questions for paid work or schoolwork, 2 questions for household work, and 1 question for family, social and leisure activities. The 2 questions for each of the first two groups assess, respectively, the number of days off due to headache, and the number of days in which the productivity was reduced by half or more. mMIDAS total score was derived from the sum of the answers on the first 5 questions. Total score ranged from 0 (little/no disability) to 20 (severe disability) with higher scores indicating more severe disability.

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Least squares mean · units on a scale
Placebo-controlled Period: Change From Baseline in Modified Migraine Disability Assessment (mMIDAS) Total Score at Weeks 4 and 12
units on a scalePlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Change at Week 4-14.73 ± 1.475-6.62 ± 1.476
Change at Week 12-13.83 ± 1.494-8.76 ± 1.496
SecondaryOpen-label Period: Change From Baseline in mMIDAS Total Score at Week 24

The mMIDAS is a self-administered questionnaire that contains 7 questions about the headache a participant had in the previous month. The first 5 questions assess the impact of migraine on 3 domains of daily activity: 2 questions for paid work or schoolwork, 2 questions for household work, and 1 question for family, social and leisure activities. The 2 questions for each of the first two groups assess, respectively, the number of days off due to headache, and the number of days in which the productivity was reduced by half or more. mMIDAS total score was derived from the sum of the answers on the first 5 questions. Total score ranged from 0 (little/no disability) to 20 (severe disability) with higher scores indicating more severe disability.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Open-label Period: Change From Baseline in mMIDAS Total Score at Week 24
units on a scaleOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Open-label Period: Change From Baseline in mMIDAS Total Score at Week 24-17.3 ± 20.71-15.2 ± 19.69
SecondaryPlacebo-controlled Period: Change From Baseline in Migraine-Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Weeks 4 and 12

The MSQ v2.1 is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0-to-100-point scale. Higher scores indicated better quality of life.

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Least squares mean · units on a scale
Placebo-controlled Period: Change From Baseline in Migraine-Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Weeks 4 and 12
units on a scalePlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Change at Week 4: Role function- restrictive24.04 ± 1.89810.15 ± 1.902
Change at Week 12: Role function- restrictive22.55 ± 1.87311.79 ± 1.877
Change at Week 4: Role function- preventive18.58 ± 1.8627.88 ± 1.864
Change at Week 12: Role function- preventive17.96 ± 1.83410.16 ± 1.836
Change at Week 4: Emotional function23.82 ± 2.14310.11 ± 2.145
Change at Week 12: Emotional function22.06 ± 2.18811.67 ± 2.193
SecondaryOpen-label Period: Change From Baseline in MSQ v2.1 Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 24

The MSQ v2.1 is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0-to-100-point scale. Higher scores indicated better quality of life.

Time frame:
Baseline, Weeks 24
Reported as:
Least squares mean · units on a scale
Open-label Period: Change From Baseline in MSQ v2.1 Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 24
units on a scaleOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Role function- restrictive26.38 ± 23.30226.33 ± 24.159
Role function- preventive20.6 ± 23.6120.7 ± 22.85
Emotional function26.86 ± 27.80626.54 ± 28.385
SecondaryPlacebo-controlled Period: Change From Baseline in Euroqol 5 Dimension - 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Weeks 4 and 12

The EQ-5D-5L VAS measures participant's self-rated health-related quality of life on a VAS. The VAS score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Least squares mean · units on a scale
Placebo-controlled Period: Change From Baseline in Euroqol 5 Dimension - 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Weeks 4 and 12
units on a scalePlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Change at Week 45.09 ± 1.5610.49 ± 1.574
Change at Week 127.43 ± 1.5262.23 ± 1.540
SecondaryOpen-label Period: Change From Baseline in EQ-5D-5L VAS Score at Week 24

The EQ-5D-5L VAS measures participant's self-rated health-related quality of life on a VAS. The VAS score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Week 24
Reported as:
Mean · units on a scale
Open-label Period: Change From Baseline in EQ-5D-5L VAS Score at Week 24
units on a scaleOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Open-label Period: Change From Baseline in EQ-5D-5L VAS Score at Week 245.9 ± 22.693.9 ± 22.10
SecondaryPlacebo-controlled Period: Change From Baseline in Work Productivity and Activity Impairment: Migraine (WPAI:M) Sub-scores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 12

The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Placebo-controlled Period: Change From Baseline in Work Productivity and Activity Impairment: Migraine (WPAI:M) Sub-scores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 12
units on a scalePlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Absenteeism-4.73 ± 2.342-1.18 ± 2.324
Presenteeism-19.10 ± 2.602-10.12 ± 2.544
Work productivity loss-19.88 ± 2.790-9.04 ± 2.727
Activity impairment-18.87 ± 2.065-10.42 ± 2.079
SecondaryOpen-label Period: Change From Baseline in WPAI:M Sub-scores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 24

The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Open-label Period: Change From Baseline in WPAI:M Sub-scores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 24
units on a scaleOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Absenteeism-9.22 ± 27.236-4.75 ± 25.007
Presenteeism-18.8 ± 28.41-22.7 ± 27.58
Work productivity loss-20.54 ± 29.162-24.18 ± 29.102
Activity impairment-19.6 ± 28.14-21.0 ± 28.73
SecondaryPlacebo-controlled Period: Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Subscale (Depression and Anxiety) Scores at Weeks 4 and 12

The HADS is a participant-rated scale designed to assess psychological distress in non-psychiatric participants. The HADS consists of 2 sub-scales: depression and anxiety. Each sub-scale contains 7 items, and each item was rated from 0 (absent) to 3 (maximum severity). The total score of each sub-scale ranged from 0 (absent) to 21 (maximum severity). Higher scores indicated higher severity.

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Least squares mean · units on a scale
Placebo-controlled Period: Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Subscale (Depression and Anxiety) Scores at Weeks 4 and 12
units on a scalePlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Change at Week 4: Total Depression Score-1.59 ± 0.294-0.61 ± 0.296
Change at Week 12: Total Depression Score-1.82 ± 0.300-0.64 ± 0.302
Change at Week 4: Total Anxiety Score-1.32 ± 0.262-0.49 ± 0.263
Change at Week 12: Total Anxiety Score-1.37 ± 0.257-0.40 ± 0.257
SecondaryOpen-label Period: Change From Baseline in HADS Subscale (Depression and Anxiety) Scores at Week 24

The HADS is a participant-rated scale designed to assess psychological distress in non-psychiatric participants. The HADS consists of 2 sub-scales: depression and anxiety. Each sub-scale contains 7 items, and each item was rated from 0 (absent) to 3 (maximum severity). The total score of each sub-scale ranged from 0 (absent) to 21 (maximum severity). Higher scores indicated higher severity.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Open-label Period: Change From Baseline in HADS Subscale (Depression and Anxiety) Scores at Week 24
units on a scaleOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Total Depression Score-2.1 ± 3.78-1.3 ± 3.88
Total Anxiety Score-2.0 ± 3.36-1.1 ± 3.54
SecondaryPlacebo-controlled Period: Treatment Satisfaction Questionnaire for Medicine - 9 Items (TSQM-9) Score at Weeks 4 and 12

TSQM is a 14-item instrument consisting of four scales: effectiveness scale (questions 1 to 3), side effects scale (questions 4 to 8), convenience scale (questions 9 to 11) and global satisfaction scale (questions 12 to 14). In TSQM-9, the five items related to side effects of medication were not included. The scores were computed by adding items for each domain. The lowest possible score was subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.

Time frame:
Weeks 4 and 12
Reported as:
Least squares mean · units on a scale
Placebo-controlled Period: Treatment Satisfaction Questionnaire for Medicine - 9 Items (TSQM-9) Score at Weeks 4 and 12
units on a scalePlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Week 4: Effectiveness Score58.21 ± 2.22839.01 ± 2.236
Week 12: Effectiveness Score57.95 ± 2.26440.89 ± 2.278
Week 4: Convenience Score69.60 ± 1.73663.62 ± 1.743
Week 12: Convenience Score69.42 ± 1.78663.12 ± 1.797
Week 4: Overall Satisfaction Score59.56 ± 2.09443.57 ± 2.099
Week 12: Overall Satisfaction Score62.54 ± 2.13646.98 ± 2.146
SecondaryOpen-label Period: TSQM-9 Score at Week 24

TSQM is a 14-item instrument consisting of four scales: effectiveness scale (questions 1 to 3), side effects scale (questions 4 to 8), convenience scale (questions 9 to 11) and global satisfaction scale (questions 12 to 14). In TSQM-9, the five items related to side effects of medication were not included. The scores were computed by adding items for each domain. The lowest possible score was subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Open-label Period: TSQM-9 Score at Week 24
units on a scaleOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
Effectiveness Score63.23 ± 28.68462.50 ± 27.896
Convenience Score66.23 ± 21.45166.02 ± 23.017
Overall Satisfaction Score64.23 ± 29.40163.51 ± 27.603
SecondaryPlacebo-controlled Period: Migraine Specific Health Care Resource Utilization (HCRU) - Visits to a Family Doctor/General Practitioner at Baseline and Week 12

Number of participants who visited to a family doctor/general practitioner during the past 4 weeks has been reported at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Placebo-controlled Period: Migraine Specific Health Care Resource Utilization (HCRU) - Visits to a Family Doctor/General Practitioner at Baseline and Week 12
ParticipantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Baseline — 0 Visit213198
Baseline — 1 Visit4442
Baseline — 2 Visits1017
Baseline — 3 Visits114
Baseline — 4 Visits23
Baseline — 5 Visits12
Baseline — 6 Visits10
Baseline — 10 Visits10
Baseline — 15 Visits01
Week 12 — 0 Visit242217
Week 12 — 1 Visit2941
Week 12 — 2 Visits715
Week 12 — 3 Visits54
Week 12 — 4 Visits42
Week 12 — 5 Visits02
Week 12 — 6 Visits10
Week 12 — 10 Visits00
Week 12 — 15 Visits00
SecondaryPlacebo-controlled Period: Migraine Specific HCRU - Visits to a Specialist at Baseline and Week 12

Number of participants who visited a specialist during the past 4 weeks has been reported at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Placebo-controlled Period: Migraine Specific HCRU - Visits to a Specialist at Baseline and Week 12
ParticipantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Baseline — 0 Visit180156
Baseline — 1 Visit7183
Baseline — 2 Visits2118
Baseline — 3 Visits65
Baseline — 4 Visits32
Baseline — 5 Visits12
Baseline — 6 Visits10
Baseline — 12 Visits01
Week 12 — 0 Visit245224
Week 12 — 1 Visit3043
Week 12 — 2 Visits78
Week 12 — 3 Visits15
Week 12 — 4 Visits41
Week 12 — 5 Visits10
Week 12 — 6 Visits00
Week 12 — 12 Visits00
SecondaryPlacebo-controlled Period: Migraine Specific HCRU - Number of Emergency Department Visits Due to Migraine at Baseline and Week 12

Number of participants who visited to the emergency department due to migraine during the past 4 weeks has been reported at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Placebo-controlled Period: Migraine Specific HCRU - Number of Emergency Department Visits Due to Migraine at Baseline and Week 12
ParticipantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Baseline — 0 Visit275256
Baseline — 1 Visit77
Baseline — 2 Visits13
Baseline — 9 Visits01
Week 12 — 0 Visit281268
Week 12 — 1 Visit510
Week 12 — 2 Visits23
Week 12 — 9 Visits00
SecondaryPlacebo-controlled Period: Migraine Specific HCRU - Number of Hospital Admissions Migraine at Baseline and Week 12

Number of participants who were admitted to the hospital during the past 4 weeks due to migraine has been reported at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Placebo-controlled Period: Migraine Specific HCRU - Number of Hospital Admissions Migraine at Baseline and Week 12
ParticipantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Baseline — 0 Admission279258
Baseline — 1 Admission37
Baseline — 2 Admissions11
Baseline — 16 Admissions01
Week 12 — 0 Admission286277
Week 12 — 1 Admission24
Week 12 — 2 Admissions00
Week 12 — 16 Admissions00
SecondaryPlacebo-controlled Period: Migraine Specific HCRU - Total Number of Participants With Overnight Hospital Stays Due to Migraine at Baseline and Week 12

Number of participants who had overnight hospital stays during the past 4 weeks due to migraine has been reported at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Placebo-controlled Period: Migraine Specific HCRU - Total Number of Participants With Overnight Hospital Stays Due to Migraine at Baseline and Week 12
ParticipantsPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: Placebo
Baseline — 0 Stay282264
Baseline — 1 Stay11
Baseline — 2 Stays01
Baseline — 7 Stays01
Week 12 — 0 Stay287278
Week 12 — 1 Stay13
Week 12 — 2 Stays00
Week 12 — 7 Stays00
SecondaryOpen-label Period: Migraine Specific HCRU - Visits to a Family Doctor/General Practitioner at Week 24

Number of participants who visited a family doctor/general practitioner has been reported.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Open-label Period: Migraine Specific HCRU - Visits to a Family Doctor/General Practitioner at Week 24
ParticipantsOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
0 Visit239239
1 Visit2620
2 Visits1113
3 Visits31
4 Visits10
5 Visits01
7 Visits01
8 Visits00
13 Visits10
SecondaryOpen-label Period: Migraine Specific HCRU - Visits to a Specialist at Week 24

Number of participants who visited a specialist has been reported.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Open-label Period: Migraine Specific HCRU - Visits to a Specialist at Week 24
ParticipantsOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
0 Visit239240
1 Visit2920
2 Visits78
3 Visits34
4 Visits12
5 Visits01
6 Visits10
7 Visits10
SecondaryOpen-label Period: Migraine Specific HCRU - Number of Participants With Emergency Department Visits Due to Migraine at Week 24

Number of participants who visited the emergency department due to migraine has been reported.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Open-label Period: Migraine Specific HCRU - Number of Participants With Emergency Department Visits Due to Migraine at Week 24
ParticipantsOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
0 Visit277265
1 Visit35
2 Visits03
3 Visits01
10 Visits01
18 Visits10
SecondaryOpen-label Period: Migraine Specific HCRU - Number of Participants With Hospital Admissions Due to Migraine at Week 24

Number of participants who admitted in the hospital due to migraine has been reported.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Open-label Period: Migraine Specific HCRU - Number of Participants With Hospital Admissions Due to Migraine at Week 24
ParticipantsOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
0 Admission281271
1 Admission02
2 Admissions02
SecondaryOpen-label Period: Migraine Specific HCRU - Number of Participants With Overnight Hospital Stays Due to Migraine at Week 24

Number of participants with overnight hospital stays due to migraine has been reported.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Open-label Period: Migraine Specific HCRU - Number of Participants With Overnight Hospital Stays Due to Migraine at Week 24
ParticipantsOpen-label Period: Eptinezumab - EptinezumabOpen-label Period: Placebo - Eptinezumab
0 Stay281270
1 Stays03
2 Stays01
12 Stays01

Adverse events

Collected over Up to 32 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-controlled Period: Eptinezumab0/303 (0%)2/303 (0.7%)50/303 (16.5%)
Placebo-controlled Period: Placebo0/301 (0%)1/301 (0.3%)55/301 (18.3%)
Open-label Period: Eptinezumab to Eptinezumab0/300 (0%)2/300 (0.7%)30/300 (10%)
Open-label Period: Placebo to Eptinezumab0/293 (0%)5/293 (1.7%)42/293 (14.3%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: PlaceboOpen-label Period: Eptinezumab to EptinezumabOpen-label Period: Placebo to Eptinezumab
HaemorrhoidsGastrointestinal disorders0/3030/3010/3001/293
Breast cancer stage IIINeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3030/3010/3001/293
MigraineNervous system disorders0/3030/3010/3001/293
SyncopeNervous system disorders0/3030/3010/3001/293
Transient ischaemic attackNervous system disorders0/3030/3010/3001/293
Suicide attemptPsychiatric disorders0/3030/3010/3001/293
Chest painGeneral disorders0/3030/3011/3000/293
Ankle fractureInjury, poisoning and procedural complications0/3030/3011/3000/293
Drug abusePsychiatric disorders0/3031/3010/3000/293
AppendicitisInfections and infestations1/3030/3010/3000/293
Most frequent other events
Most frequent other events
EventPlacebo-controlled Period: EptinezumabPlacebo-controlled Period: PlaceboOpen-label Period: Eptinezumab to EptinezumabOpen-label Period: Placebo to Eptinezumab
NasopharyngitisInfections and infestations15/30317/3017/30010/293
FatigueGeneral disorders6/30311/3016/3005/293
InfluenzaInfections and infestations11/30310/3017/3006/293
DizzinessNervous system disorders8/3039/3011/3008/293
InsomniaPsychiatric disorders2/3038/3012/3003/293
Back painMusculoskeletal and connective tissue disorders5/3037/3013/3004/293
AstheniaGeneral disorders3/3033/3011/3006/293
COVID-19Infections and infestations6/3034/3015/3006/293

Baseline characteristics

All-Participants-Treated Set (APTS) included all randomized participants who received an infusion of the IMP in the Placebo-controlled Period.

Age, Continuous
Age, Continuous(years)EptinezumabPlaceboTotal
Mean45.7 ± 11.9545.2 ± 12.0345.5 ± 11.98
Sex: Female, Male
Sex: Female, Male(Participants)EptinezumabPlaceboTotal
Female264253517
Male394887
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EptinezumabPlaceboTotal
Race — White151147298
Race — Black347
Race — Asian112
Race — Other246
Race — Not Collected/Unknown146145291
Monthly Migraine Days (MMDs)
Monthly Migraine Days (MMDs)(days/month)EptinezumabPlaceboTotal
Mean21.0 ± 4.2620.9 ± 4.2820.9 ± 4.27
08

Study locations

76 sites
  • Clinical Research of Central Florida - ClinEdge - PPDS
    Winter Haven, Florida 33880-3053, United States
  • Legacy Clinical Solutions: Tandem Clinical Research LLC - Medical Center - Marrero - ClinEdge - PPDS
    Marrero, Louisiana 70072-3083, United States
  • Clinvest - National Ave - Headlands - PPDS
    Springfield, Missouri 65807-6012, United States
  • Dent Neurologic Institute - Amherst
    Amherst, New York 14226-1727, United States
  • Headache Center - Montefiore Medical Center - BRANY - PPDS
    The Bronx, New York 10461-2732, United States
  • Texas Center for Drug Development, Inc
    Houston, Texas 77081, United States
  • Southern Neurology
    Kogarah, New South Wales 2217, Australia
  • Mater Adult Hospital
    South Brisbane, Queensland 4101, Australia
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
  • Alfred Health
    Melbourne, Victoria 3004, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3052, Australia
  • Danish Headache Center
    Glostrup Municipality, Capital 2600, Denmark
  • Sydvestjysk Sygehus Esbjerg
    Esbjerg, 6700, Denmark
  • CHU de Nice
    Nice, Alpes-Maritimes 06000, France
  • Assistance Publique Hopitaux de Marseille
    Marseille, Bouches-du-Rhône 13385, France
  • Hôpital Pierre-Paul Riquet
    Toulouse, Haute-Garonne 31000, France
  • Centre Hospitalier Annecy Genevois - Site d'Annecy
    Pringy, Haute-Savoie 74374, France
  • CHRU Nantes
    Saint-Herblain, Loire-Atlantique 44800, France
  • Hôpital Roger Salengro
    Lille, Nord 59000, France
  • Centre Hospitalier Universitaire de Saint Etienne
    Saint-Priest-en-Jarez, Pays de la Loire Region 42055, France
  • Centre Hospitalier Universitaire de Clermont Ferrand -58 Rue Montalembert
    Clermont-Ferrand, Puy-de-Dôme 63003, France
  • Hospices Civils de Lyon - Hôpital Pierre Wertheimer
    Bron, Rhône 69500, France
  • AP-HP - Hopital Lariboisiere
    Paris, 75010, France
  • Groupe Hospitalier Paris Saint Joseph
    Paris, 75014, France
  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center-Gobronidze 10
    Tbilisi, 0101, Georgia
  • Ltd Israel-Georgia Medical Research Clinic Helsicore
    Tbilisi, 0112, Georgia
  • Pineo Medical Ecosystem
    Tbilisi, 0114, Georgia
  • Aversi Clinic LTD
    Tbilisi, 0160, Georgia
  • MediClubGeorgia Ltd
    Tbilisi, 0160, Georgia
  • S. Khechinashvili University Clinic, Ltd.
    Tbilisi, 0179, Georgia
  • Multiprofile Clinic Consilium Medulla
    Tbilisi, 0186, Georgia
  • Klinikverbund Südwest - Kliniken Sindelfingen
    Sindelfingen, Baden-Wurttemberg 71065, Germany
  • Kopfschmerzzentrum Frankfurt
    Frankfurt am Main, Hesse 65929, Germany
  • Studienzentrum Nord-West
    Westerstede, Lower Saxony 26655, Germany
  • Praxis fuer Neurologie, Spezielle Schmerztherapie und Psychotherapie
    Essen, North Rhine-Westphalia 45133, Germany
  • Universitätsklinikum Essen
    Essen, North Rhine-Westphalia 45147, Germany
  • Universitätsklinikum Carl Gustav Carus an der TU Dresden
    Dresden, Saxony 01307, Germany
  • Universitatsklinikum Jena - Am Klinikum 1-Erlanger Allee 101
    Jena, Thuringia 07747, Germany
  • Universitätsmedizin Greifswald
    Greifswald, 17475, Germany
  • ASL 1 Abruzzo - PO Avezzano
    Avezzano, Abruzzo 67051, Italy
  • Azienda Ospedaliero Universitaria Consorziale Policlinico
    Bari, Apulia 70124, Italy
  • Azienda Ospedaliera Universitaria Luigi Vanvitelli - Piazza Luigi Miraglia 2
    Naples, Campania 80138, Italy
  • IRCCS Istituto delle Scienze Neurologiche - Largo B. Nigrisoli
    Bologna, Emilia-Romagna 40139, Italy
  • Fondazione Policlinico Universitario Campus Bio-Medico
    Rome, Lazio 00128, Italy
  • IRCCS San Raffaele
    Rome, Lazio 00163, Italy
  • Fondazione Policlinico Universitario A Gemelli - Rome - PPDS
    Rome, Lazio 00168, Italy
  • Ospedale San Raffaele S.r.l. - PPDS
    Milan, Lombardy 20127, Italy
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Milan, Lombardy 20133, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Florence, Tuscany 50134, Italy
  • Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia
    Perugia, Umbria 06129, Italy
  • Azienda Ospedaliero Universitaria Di Modena Policlinico
    Modena, 41100, Italy
  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone-Palermo-Piazza Delle Cliniche 2
    Palermo, 90127, Italy
  • Fondazione Istituto Neurologico Nazionale Casimiro Mondino IRCCS
    Pavia, 27100, Italy
  • Leids Universitair Medisch Centrum
    Leiden, South Holland 2333 ZA, Netherlands
  • Akershus Universitetssykehus
    Nordbyhagen, Akershus 1474, Norway
  • Haukeland Universitetssykehus
    Bergen, Hordaland 5021, Norway
  • St. Olav's University Hospital
    Trondheim, Sør-Trøndelag 7006, Norway
  • Oslo Universitetssykehus
    Oslo, Norway
  • Hospital Puerta del Mar
    Cadiz, Cádiz 11009, Spain
  • C.H. Regional Reina Sofia - PPDS
    Córdoba, Córdoba 14004, Spain
  • Hospital Universitario Puerta de Hierro - Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital General Universitario Dr. Balmis
    Alicante, 03010, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Universitario Vall d'Hebron - PPDS
    Barcelona, 8035, Spain
  • Hospital Universitari Arnau de Vilanova
    Lleida, 25198, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario HM Sanchinarro - CIOCC
    Madrid, 28050, Spain
  • Hospital Universitario Virgen del Rocio - PPDS
    Seville, 41013, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Hospital Clinico Universitario de Valladolid
    Valladolid, 47010, Spain
  • Hospital Clinico Universitario Lozano Blesa
    Zaragoza, 50009, Spain
  • Hallands Sjukhus Halmstad
    Halmstad, Halland County 301 85, Sweden
  • Skaneuro Privatmottagning
    Lund, Skåne County 227 33, Sweden
  • Karolinska Universitetssjukhuset Huddinge
    Huddinge, Stockholm County 141 52, Sweden
  • CTC Clinical Trial Consultants AB
    Solna, Stockholm County 176 64, Sweden
09

References and documents

Publications

  • Schytz HW, Jensen RH, Lundqvist C, Tassorelli C, Vernieri F, Lanteri-Minet M, Terwindt GM, Blumenfeld A, Tepper SJ, Josiassen MK, Jansson G, Ettrup A, Mittoux A, Lipton RB. Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: 24-week results of the randomized RESOLUTION trial. J Headache Pain. 2026 Jun 13;27(1):157. doi: 10.1186/s10194-026-02423-x. PubMed 42288801 ↗
  • Tepper SJ, Schytz HW, Jensen RH, Lundqvist C, Terwindt GM, Tassorelli C, Vernieri F, Lanteri-Minet M, Blumenfeld A, Josiassen MK, Jansson G, Ettrup A, Mittoux A, Lipton RB. Benefits of eptinezumab on patient-reported disease burden and health-related quality of life in adults with chronic migraine and medication-overuse headache: Results from the placebo-controlled RESOLUTION trial. Cephalalgia. 2026 May;46(5):3331024261449814. doi: 10.1177/03331024261449814. Epub 2026 May 16. PubMed 42142011 ↗
  • Jensen RH, Lundqvist C, Schytz HW, Tassorelli C, Vernieri F, Lanteri-Minet M, Terwindt GM, Blumenfeld A, Tepper SJ, Josiassen MK, Jansson G, Ettrup A, Mittoux A, Lipton RB. Eptinezumab With Patient Education for Chronic Migraine and Medication-Overuse Headache: The Randomized, Placebo-Controlled RESOLUTION Trial. Neurology. 2026 Apr 28;106(8):e214863. doi: 10.1212/WNL.0000000000214863. Epub 2026 Mar 26. PubMed 41886713 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Oct 2024, 27 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 27 months is close to that.

Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2022
First posted
Jul 11, 2022
StartActual
Jul 1, 2022
Primary completionActual
Oct 22, 2024
CompletionActual
Mar 13, 2025
Results first posted
Dec 4, 2025
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05452239
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Jul 1, 2022
Primary completion
Oct 22, 2024
Completion
Mar 13, 2025
Results posted
Dec 4, 2025
Last update
Jan 29, 2026

Study contacts

Email contact via H. Lundbeck A/S
study director · HQ_Medinfo@Lundbeck.com

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion